Prophet4me, Comparing Gilead to Peter Cook is like comparing Albert Einstein to Bernard Madoff.
Why, you may ask? 1) Gilead management sued Roche but quickly settled with an increased 20% royalty plus increased production capacity and went on to benefit from the swine flu outbreak at the expense of BTA share holders. IMHO It possibly may have stopped Roche from venturing into pandamic flu research. – Compare this to: Turning down $100million GSK offer, and selling out for $20m after spending more than $30m in legal costs and with GSK embarking on Pandemic Flu Vaccine that compete with Relenza for pandemic preparation monies. The most incredible is Peter Idiot had the nerve to blame the financial loss of his utmost idiotic settlement on Peter Molloy and then asked shareholders to vote for a resolution awarding him 403,600 options, and despite shareholders voting down the resolution, the idiot collect his 403,600 options and announce it on 17 December thinking shareholders were too busy celebrating Xmas to notice. See the Madoff factor?
2) Despite all the problems (Tamiflu psychotic problems, resistance to H1N1 seasonal flu virus and swine-flu H1N1 virus), Roche sold 1billion Swiss frank of Tamiflu. What was Relenza sales? Wow, Peter Cook had the tenacity to claim credit that his cooked settlement has normalised GSK relationship!
3) Roche is increasing annual production capacity to 400 million packs compared to GSK’s 190 million courses. See the difference?
4) GSK presold 195 million doses of Pandemic vaccines, 2 billion$ investment in pandemic flu, how much for Relenza?
Is it not clear? Why did Peter Cook announced Quote: ''The expansion of Relenza capacity and any increase in resultant royalty payments, will not effect Biotas cash position until June 2010, at the earliest'' When HC readers who had been following BTA can misinterpret it as meaning “royalties will not be booked until June 2010 at the earliest”, you think Peter Cook is not aware the market will not be misled?
IF management is a fraction as good as the Gilead management, Biota sp would be more successful than CSL. However, the royalties from Relenza and the potential of LANI has not been recognised in the $1.76 sp.- because the idiot Peter Cook failed to announce good news such as extension of the Patents and the idiot is still talking down the sp.
At $1.76 x 175 million shares, the market capitalisation is less than the $300 million p.a Relenza royalties from the 190m courses production.
BTA Price at posting:
$1.76 Sentiment: None Disclosure: Not Held
